Trial Outcomes & Findings for Effect of Snacks on Appetite Control (NCT NCT01806688)

NCT ID: NCT01806688

Last Updated: 2021-08-12

Results Overview

Appetite assessment was measured using a VAS questionnaire administered pre-snack and every 30 minutes post snack up to 180 minutes, for a total of 7 time points. The questionnaire included 4 questions (1) How hungry are you? (2) How full are you? (3) How strong is your desire to eat? (4) How much do you think you want to eat right now? Each question was followed by a 10 cm line anchored at the left and right ends by the opposing statements "not at all" and "extremely" for questions 1 and 2, "very weak " and "very strong" for question 3, and "nothing at all" and "a very large amount" for question 4. Participants provided their response to each question by marking a perpendicular line on the 10-cm line to indicate their answer. Scores were determined by measuring the distance in centimeters from the left anchor to the perpendicular line drawn by the participant. VAS scores over time were graphed and AUC was calculated using the trapezoid method.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

46 participants

Primary outcome timeframe

VAS administered pre-snack and then every 30 minutes after the first bite up to 180 minutes for a total of 7 time points.

Results posted on

2021-08-12

Participant Flow

289 candidates were screened between June 2013 and August 2014. Of these 289 candidates, 50 met the criteria and were determined to be eligible. The first participant was enrolled on July 6, 2013 and the last participant enrolled August 9, 2014. 46 participants were enrolled in the overall study and 30 of these completed both the seed study and the pita study while 16 participated in only one of the studies. 38 participants were randomized to the seed study and 38 to the pita study.

30 people completed both studies and 16 participated in only 1 study.

Participant milestones

Participant milestones
Measure
Seed Study
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
Pita Study
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of a buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
First Intervention Seed Study
STARTED
38
0
First Intervention Seed Study
Experimental Snack #1
13
0
First Intervention Seed Study
Placebo Comparator Reference Product #1
13
0
First Intervention Seed Study
Placebo Comparator Non-caloric Control #1
12
0
First Intervention Seed Study
COMPLETED
38
0
First Intervention Seed Study
NOT COMPLETED
0
0
Second Intervention Seed Study
STARTED
38
0
Second Intervention Seed Study
Experimental Snack #1
13
0
Second Intervention Seed Study
Placebo Comparator Reference Product #1
13
0
Second Intervention Seed Study
Placebo Comparator Non-caloric Control #1
12
0
Second Intervention Seed Study
COMPLETED
38
0
Second Intervention Seed Study
NOT COMPLETED
0
0
Third Intervention Seed Study
STARTED
38
0
Third Intervention Seed Study
Experimental Snack #1
12
0
Third Intervention Seed Study
Placebo Comparator Reference Product #1
12
0
Third Intervention Seed Study
Placebo Comparator Non-caloric Control #1
14
0
Third Intervention Seed Study
COMPLETED
38
0
Third Intervention Seed Study
NOT COMPLETED
0
0
First Intervention Pita Study
STARTED
0
38
First Intervention Pita Study
Experimental Snack #2
0
14
First Intervention Pita Study
Placebo Comparator Reference Product #2
0
12
First Intervention Pita Study
Placebo Comparator Non-caloric Control #2
0
12
First Intervention Pita Study
COMPLETED
0
38
First Intervention Pita Study
NOT COMPLETED
0
0
Second Intervention Pita Study
STARTED
0
38
Second Intervention Pita Study
Experimental Snack #2
0
12
Second Intervention Pita Study
Placebo Comparator Reference Product #2
0
13
Second Intervention Pita Study
Placebo Comparator Non-caloric Control #2
0
13
Second Intervention Pita Study
COMPLETED
0
38
Second Intervention Pita Study
NOT COMPLETED
0
0
Third Intervention Pita Study
STARTED
0
38
Third Intervention Pita Study
Experimental Snack #2
0
12
Third Intervention Pita Study
Placebo Comparator Reference Product #2
0
13
Third Intervention Pita Study
Placebo Comparator Non-caloric Control #2
0
13
Third Intervention Pita Study
COMPLETED
0
38
Third Intervention Pita Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Seed Study
n=38 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
Pita Study
n=38 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
Total
n=76 Participants
Total of all reporting groups
Age, Categorical
Seed Study · <=18 years
0 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Categorical
Seed Study · Between 18 and 65 years
37 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
37 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Categorical
Seed Study · >=65 years
1 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
1 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Categorical
Pita Study · <=18 years
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
0 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Categorical
Pita Study · Between 18 and 65 years
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
37 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
37 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Categorical
Pita Study · >=65 years
0 Participants
289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
1 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
1 Participants
n=38 Participants • 289 candidates were screened for the study between June 2013 and August 2014. Of those 289 candidates, 50 met the inclusion criteria and of those 50, a total of 46 were enrolled in the overall study. 38 were randomized to treatment in the Seed Study and 38 were randomized to treatment in the Pita Study. 30 completed both studies and 16 chose to do just one study.
Age, Continuous
Seed Study
37.7 years
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
37.7 years
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Age, Continuous
Pita Study
33.5 years
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
33.5 years
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Sex: Female, Male
Seed Study · Female
10 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
10 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Sex: Female, Male
Seed Study · Male
28 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
28 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Sex: Female, Male
Pita Study · Female
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
11 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
11 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Sex: Female, Male
Pita Study · Male
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
27 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
27 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · American Indian or Alaska Native
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · Asian
9 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
9 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · Native Hawaiian or Other Pacific Islander
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · Black or African American
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · White
24 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
24 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · More than one race
2 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
2 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Seed Study · Unknown or Not Reported
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · American Indian or Alaska Native
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · Asian
11 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
11 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · Native Hawaiian or Other Pacific Islander
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
0 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · Black or African American
1 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
1 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · White
20 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
20 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · More than one race
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Race (NIH/OMB)
Pita Study · Unknown or Not Reported
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
3 Participants
n=38 Participants • A total of 46 participants were enrolled in the overall study, and of those 46 enrolled, 30 participated in both studies while 16 only participated in one study. 38 participants were randomized to complete the Seed Study and 38 participants to complete the Pita Study.
Region of Enrollment
Canada
0 Participants
Data collected from the two studies are reported in separate Baseline Measures
38 Participants
n=38 Participants • Data collected from the two studies are reported in separate Baseline Measures
38 Participants
n=38 Participants • Data collected from the two studies are reported in separate Baseline Measures

PRIMARY outcome

Timeframe: VAS administered pre-snack and then every 30 minutes after the first bite up to 180 minutes for a total of 7 time points.

Population: A total of 46 participants were enrolled in the Seed and the Pita Study. Of these 46, 30 participated in both studies and 16 enrolled in just one study. 38 participants enrolled in the Seed Study and 38 in the Pita Study.

Appetite assessment was measured using a VAS questionnaire administered pre-snack and every 30 minutes post snack up to 180 minutes, for a total of 7 time points. The questionnaire included 4 questions (1) How hungry are you? (2) How full are you? (3) How strong is your desire to eat? (4) How much do you think you want to eat right now? Each question was followed by a 10 cm line anchored at the left and right ends by the opposing statements "not at all" and "extremely" for questions 1 and 2, "very weak " and "very strong" for question 3, and "nothing at all" and "a very large amount" for question 4. Participants provided their response to each question by marking a perpendicular line on the 10-cm line to indicate their answer. Scores were determined by measuring the distance in centimeters from the left anchor to the perpendicular line drawn by the participant. VAS scores over time were graphed and AUC was calculated using the trapezoid method.

Outcome measures

Outcome measures
Measure
Seed Study
n=37 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
Pita Study
n=37 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density but less protein and fiber than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Experimental Snack #1 Hunger
651 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Experimental Snack #1 Fullness
1008 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Experimental Snack #1 Desire
638 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Experimental Snack #1 Consume
640 cm x min
Standard Error 42
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator #1 Hunger
636 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator #1 Fullness
1024 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator #1 Desire
659 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator #1 Consume
649 cm x min
Standard Error 42
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator #1 Non-caloric Control Hunger
962 cm x min
Standard Error 46
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Control #1 Non-caloric Control Fullness
682 cm x min
Standard Error 47
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Control #1 Non-caloric Control Desire
980 cm x min
Standard Error 47
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Seed Study Placebo Comparator Non-caloric Control #1 Consume
916 cm x min
Standard Error 42
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Experimental Snack #2 Hunger
611 cm x min
Standard Error 40
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Experimental Snack #2 Fullness
1005 cm x min
Standard Error 41
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Experimental Snack #2 Desire
616 cm x min
Standard Error 44
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Experimental Snack #2 Consume
599 cm x min
Standard Error 38
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Reference Product Hunger
661 cm x min
Standard Error 39
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Reference Product Fullness
968 cm x min
Standard Error 40
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Reference Product Desire
682 cm x min
Standard Error 43
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Reference Product Consume
676 cm x min
Standard Error 38
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Non-caloric Control Hunger
956 cm x min
Standard Error 39
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Non-caloric Control Fullness
675 cm x min
Standard Error 40
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Non-caloric Control Desire
1001 cm x min
Standard Error 43
Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS)
Pita Study Placebo Comparator #2 Non-caloric Control Consume
959 cm x min
Standard Error 38

SECONDARY outcome

Timeframe: time between snack consumption and bedtime (12 hours)

Population: In the Seed Study data for 36 participants was analyzed. One participant was not analyzed due to non compliance and a second participant for not providing a food record. In the Pita Study data from 34 participants was analyzed. One participant was noncompliant and 3 did not turn in food records.

Participants were provided with a food diary to record the amount and type of each food and beverage consumed for the remainder of the day. Energy consumed at lunch and the remainder of the day were quantified from food consumed at lunch and the food diary using Food Processor Nutrient Analysis Software.

Outcome measures

Outcome measures
Measure
Seed Study
n=36 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
Pita Study
n=34 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density but less protein and fiber than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
Number of Calories Consumed Post-snack Until Bedtime
Seed Study Experimental Snack #1
1429 kcal
Standard Error 70
Number of Calories Consumed Post-snack Until Bedtime
Seed Study Placebo Comparator #1 Reference Product
1326 kcal
Standard Error 94
Number of Calories Consumed Post-snack Until Bedtime
Seed Study Placebo Comparator #1 Non-caloric Control
1288 kcal
Standard Error 80
Number of Calories Consumed Post-snack Until Bedtime
Pita Study Experimental Snack #2
1448 kcal
Standard Error 89
Number of Calories Consumed Post-snack Until Bedtime
Pita Study Placebo Comparator #2 Reference Product
1414 kcal
Standard Error 78
Number of Calories Consumed Post-snack Until Bedtime
Pita Study Placebo Comparator #2 Non-caloric Control
1478 kcal
Standard Error 75

OTHER_PRE_SPECIFIED outcome

Timeframe: 24h

Participants were asked if they noticed any gastrointestinal side effects after having eaten the study food and the results were recorded.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: immediately after eating test or reference product

Likability of the study products was assessed using a 5-point hedonic scale (1 = dislike extremely; 2 = dislike very moderately; 3 = neither like or dislike; 4 = like moderately; 5 = like extremely) for appearance, aroma, flavour, taste, texture and overall liking.

Outcome measures

Outcome measures
Measure
Seed Study
n=38 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
Pita Study
n=38 Participants
One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density but less protein and fiber than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
Likeability of Test and Reference Products Based on Sensory Scales
Experimental Snack taste
3.57 sensory rating on a scale of 1 to 5
Standard Error .2
3.66 sensory rating on a scale of 1 to 5
Standard Error .15
Likeability of Test and Reference Products Based on Sensory Scales
Experimental Snack texture
3.66 sensory rating on a scale of 1 to 5
Standard Error .19
3.49 sensory rating on a scale of 1 to 5
Standard Error .19
Likeability of Test and Reference Products Based on Sensory Scales
Experimental Snack appearance
3.57 sensory rating on a scale of 1 to 5
Standard Error .16
3.81 sensory rating on a scale of 1 to 5
Standard Error .14
Likeability of Test and Reference Products Based on Sensory Scales
Experimental Snack overall
3.48 sensory rating on a scale of 1 to 5
Standard Error .18
3.64 sensory rating on a scale of 1 to 5
Standard Error .15
Likeability of Test and Reference Products Based on Sensory Scales
Experimental Snack aroma
3.4 sensory rating on a scale of 1 to 5
Standard Error .11
3.45 sensory rating on a scale of 1 to 5
Standard Error .10
Likeability of Test and Reference Products Based on Sensory Scales
Placebo Comparator Reference taste
3.23 sensory rating on a scale of 1 to 5
Standard Error .20
3.67 sensory rating on a scale of 1 to 5
Standard Error .15
Likeability of Test and Reference Products Based on Sensory Scales
Placebo Comparator Reference texture
2.64 sensory rating on a scale of 1 to 5
Standard Error .19
3.36 sensory rating on a scale of 1 to 5
Standard Error .19
Likeability of Test and Reference Products Based on Sensory Scales
Placebo Comparator Reference appearance
3.49 sensory rating on a scale of 1 to 5
Standard Error .16
3.74 sensory rating on a scale of 1 to 5
Standard Error .14
Likeability of Test and Reference Products Based on Sensory Scales
Placebo Comparator Reference aroma
3.34 sensory rating on a scale of 1 to 5
Standard Error .11
3.39 sensory rating on a scale of 1 to 5
Standard Error .10
Likeability of Test and Reference Products Based on Sensory Scales
Placebo Comparator Reference overall
3.05 sensory rating on a scale of 1 to 5
Standard Error .18
3.58 sensory rating on a scale of 1 to 5
Standard Error .14

Adverse Events

Seed Study

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Pita Study

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Heather Blewett

Agriculture and Agri-Food Canada

Phone: 204 237-2954

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place